Current status of pluripotent stem cells: moving the first therapies to the clinic
Erin A Kimbrel1, Robert Lanza1
1Ocata Therapeutics, 33 Locke Drive, Marlborough, Massachusetts 01752, USA.
Abstract:
Pluripotent stem cells (PSCs) hold great promise for drug discovery and regenerative medicine owing to their ability to differentiate into any cell type in the body. After more than three decades of research, including delays due to the potential tumorigenicity of PSCs and inefficiencies in differentiation methods, the field is at a turning point, with a number of clinical trials across the globe now testing PSC-derived products in humans. Ocular diseases dominate these first-in-man trials, and Phase l/ll results are showing promising safety data as well as possible efficacy. In addition, the advent of induced PSC (iPSC) technology is enabling the development of a wide range of cell-based disease models from genetically predisposed patients, thereby facilitating drug discovery. In this Review, we discuss the recent progress and remaining challenges for the use of PSCs in regenerative medicine and drug development.
Insights
Pluripotent stem cells (PSCs) are advancing regenerative medicine and drug discovery. Clinical trials show promise for ocular diseases, while induced PSCs create patient-specific disease models.
Area of Science:
- Stem cell biology
- Regenerative medicine
- Drug discovery
Background:
- Pluripotent stem cells (PSCs) offer potential for cell-based therapies and drug development.
- Research faced challenges like tumorigenicity and differentiation efficiency.
- The field is progressing towards clinical applications.
Purpose of the Study:
- To review recent advancements in PSC applications for regenerative medicine.
- To discuss the role of PSCs in drug discovery and disease modeling.
- To highlight current challenges and future directions.
Main Methods:
- Review of current literature on pluripotent stem cell research.
- Analysis of clinical trial data for PSC-derived therapies.
- Discussion of induced pluripotent stem cell (iPSC) technology.
Main Results:
- PSC-derived products are entering human clinical trials, particularly for ocular diseases.
- Early Phase I/II trials indicate favorable safety and potential efficacy.
- Induced PSC technology facilitates the creation of patient-specific disease models for drug screening.
Conclusions:
- Pluripotent stem cells are nearing clinical reality in regenerative medicine.
- iPSC technology is a powerful tool for disease modeling and drug discovery.
- Continued research is needed to overcome remaining challenges for widespread therapeutic use.
More Related Videos
09:34Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions
Published on: November 27, 2017
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Stem Cell Culture
iPS Cell Differentiation
Embryonic Stem Cells
